Abstract
Between 1990 and 1997, 55 patients with high risk multiple myeloma underwent high-dose therapy with peripheral blood stem cell transplantation. Intensification consisted of high-dose L-PAM in 54 patients, and 15 patients underwent a second high-dose treatment. Thirty patients received total body irradiation. Twenty patients were more than 60 years old. Thirty-five patients were intensified during first response. The overall response rate was 78%. There were four toxic deaths. The median overall survivals after intensification and after first treatment of myeloma were greater than 48 months and 71 months, respectively. Conversely freedom from progression after intensification was short, with a median of 22 months. Freedom from progression was significantly shorter in patients older than 60 (12 months), and in patients who had received more than 75 mg/m2 of L-PAM before intensification (16 months). Although intensification is feasible in elderly patients the benefit appears to be reduced in this subgroup of patients. Prior therapy with high cumulative doses of L-PAM should be avoided in patients who will receive high-dose L-PAM for therapeutic intensification.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dumontet, C., Ketterer, N., Espinouse, D. et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 21, 1037–1041 (1998). https://doi.org/10.1038/sj.bmt.1701232
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701232
Keywords
This article is cited by
-
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
Annals of Hematology (2019)
-
Fortschritte in der Behandlung von Patienten mit multiplem Myelom
Der Onkologe (2010)
-
Autologous stem cell transplantation in the elderly including pre- and post-treatment options
Bone Marrow Transplantation (2007)
-
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
Bone Marrow Transplantation (2007)
-
Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Bone Marrow Transplantation (2006)